The Jefferies Group downgraded Isis Pharmaceuticals (NASDAQ:ISIS) this morning from a Buy rating to an Underperform, causing shares to follow suit by 10%. Zack’s, meanwhile, maintains a #3 Short-Term Hold rating on ISIS, citing pipeline product Kynamro – partnered with Sanofi’s (NYSE:SNY) Genzyme – as a catalyst in Q1 2013. Kynamro is an antisense drug to reduce LDL Cholesterol in patients with high cardiovascular risk. The company expects approval in January (PDUFA on the 29th) of next year after four Phase III studies that have successfully met all endpoints, and an ongoing study to determine broader labeling indications and dosing. If the drug is approved, Isis stands to receive a $25M milestone from Sanofi. With strong trial results and continued testing for more option in the market space, ISIS may have been oversold today. Look for a Q2 earnings announcement soon to analyze their balance sheet and Kynamro’s potential.
Incorrect Username And/Or Password
Please Complete Registration
Completing the following survey to access content
Register for FREE to access
Don't worry - this will only take a minute
Please Enter Your First Name.
Please Enter Your Last Name.
Please Enter A Valid Email.
Please Enter A Valid Password. Must Be At Least 8 Characters .
To continue with registration, you must agree to our terms of service
Already A Member? Sign In
Which Best Describes You?
Investor
Banker
Media
Other
Which Best Represents You?
Analyst
Executive
Investor Relations
SEC Attorney
Auditor
Physician
Consultant
None
Which Opportunities Interest You?
(Select All That Apply)
Please Select At Least One Interest From Each Row
Micro Cap
Small Cap
Mid/Large Cap
Biotech & Pharma
Medical Devices
Healthcare Services
Which Opportunities Interest You?
(Select All That Apply)
Please Select At Least One Interest
Investment Ideas
Trading Ideas
Healthcare News
Clinical Trials
Biz Dev
Networking
Which Opportunities Interest You?
(Select All That Apply)
Please Select At Least One Interest From Each Row
Micro Cap
Small Cap
Mid/Large Cap
Biotech & Pharma
Medical Devices
Healthcare Services
Equities
Debt
Private Placements
Which Opportunities Interest You?
(Select All That Apply)
Please Select At Least One Interest
Healthcare
Biotech
Technology
Investing
Leadership
Interviews
Conference Calls
Podcast/Webcast
Exclusive Features
News Articles
A person who either:
Earned income that exceeded $200,000 (or $300,000 together with a spouse) in each of the prior two years, and reasonably expects the same for the current year,
OR
Has a net worth over $1 million, either alone or together with a spouse (excluding the value of the person’s primary residence).
Read More here.
Yes
No
I manage or have discretionary assets of
< $5 Million
$5-$30 Million
> $30 Million
Please Select Your Asset Size
Registration Complete
You're all done! We've sent you a confirmation email that includes a verification link. To access the page you're interested in, check your email inbox(including spam folder) and click the verification link.
Four
Five
0% Complete
Please Confirm Your Email!
We've sent you a confirmation email that includes a verification link. To access the page you're interested in, check your email inbox and click the verification link.
If you cannot find it, be sure to check you "SPAM" or click "RESEND EMAIL" below.
Forgot your password?
Enter the email address associated with your account and we'll send you details on how to reset your password.
Reset Link Emailed
A email with details on resetting your password has been sent.
Your question is submitted. Our moderators are reviewing the question and will approve it shortly.
Downgrade Account
You are not logged in
Join now, it's free:
Member sign-in:
RESTRICTED ACCESS. PROPTHINK PREMIUM.
PROPTHINK PREMIUM.
Professional Edge
Actionable Trading Ideas
Proven Returns
314 ideas with avg 54% return over 5+ years
Proprietary Access
Access to Professional Research Team
Already A Member?Login
Professional Edge
Actionable Trading Ideas
Proven Returns
314 ideas with avg 54% return over 5+ years
Proprietary Access
Access to Professional Research Team
Already A Member?Login
Forgot your password?
Enter the email address associated with your account and we'll send you details shortly.
You're trying to access some of PropThink's Members-Only Content.
You can sign up for a FREE PropThink membership, unlocking significantly more of PropThink’s features, by clicking here. All it takes is an email address.
Better yet, try PropThink Premium. Click here to read more about the features of PropThink Premium, and get 50% off your first month!